A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

NCT02079805•Takeda

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Essential Hypertension Complicated by Type 2 Diabetes Mellitus

Interventions

Azilsartan

Telmisartan

Locations

Japan

Locations (1)

Kyoto, Kyoto, Japan

Key Dates

Start Date

June 1, 2014

Primary Completion Date

April 1, 2016

Completion Date

April 1, 2016

Last Updated

August 2, 2017

Sponsors

Lead Sponsor

Takeda

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 2, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions